Effect of a Chinese medical nutrition therapy diet on gut microbiota and short chain fatty acids in the simulator of the human intestinal microbial ecosystem (SHIME)

Wu, Ruiyu; Tang, Xin; Kang, Xincong; Luo, Yushuang; Wang, Lei; Li, Jian; Wu, Xiyang; Liu, Dongbo

doi:10.1016/j.jff.2019.103555

Cited by 18 publications

(7 citation statements)

References 43 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Parabacteroides is thought to provide bacteriocins to defend against the invasion of exogenous microorganisms, which would decrease in the gut microbiota after STZ treatment 10,48 . In the present study, PWE treatment increased the relative abundance of SCFA‐producing bacteria including Parabacteroides , Bacteroides , and Alloprevotella , which have been regarded as significant functional microbes with protective effects against metabolic diseases 49‐51 . Studies have reported that Akkermansia promotes regulatory immunity and delays diabetes, which can outcompete Ruminococcus from the microbiota by increasing mucus production, promoting the expression of antimicrobial peptide Reg3 γ , and reducing the serum endotoxin and expression of islet toll‐like receptor.…”

Section: Discussionsupporting

confidence: 47%

“…10,48 In the present study, PWE treatment increased the relative abundance of SCFA-producing bacteria including Parabacteroides, Bacteroides, and Alloprevotella, which have been regarded as significant functional microbes with protective effects against metabolic diseases. [49][50][51] Studies have reported that Akkermansia promotes regulatory immunity and delays diabetes, which can outcompete Ruminococcus from the microbiota by increasing mucus production, promoting the expression of antimicrobial peptide Reg3γ, and reducing the serum endotoxin and expression of islet toll-like receptor. Hänninen revealed that the abundance of Akkermansia had a negative correlation with the occurrence of T1DM-related autoantibodies.…”

Section: Discussionmentioning

confidence: 99%

See 1 more Smart Citation

Anti‐diabetic and gut microbiota modulation effects of sacha inchi (Plukenetia volubilis L.) leaf extract in streptozotocin‐induced type 1 diabetic mice

et al. 2022

View full text Add to dashboard Cite

BACKGROUND Sacha inchi (Plukenetia volubilis L.) tea has been used as an adjuvant treatment for diabetes in Pu’er, in the Yunnan province of China. The effects of sacha inchi tea on diabetes and the underlying mechanisms remain unknown. This study was conducted to investigate the influence of a water extract of sacha inchi (P. volubilis L.) leaves (PWE) on hypoglycemic activity and gut microbiota composition in mice with streptozotocin (STZ)‐induced type 1 diabetes mellitus (T1DM). During the 6 weeks of the study, T1DM mice were administered PWE intragastrically at 400 mg kg−1 body weight (BW) per day. RESULTS Treatment with PWE reduced excessive loss of BW and excessive intake of food. It significantly decreased blood glucose levels and improved oral glucose tolerance. The treatment caused protective histopathological transformations in sections of the pancreas, leading to decreased insulin resistance and improved insulin sensitivity. Treatment with PWE also significantly ameliorated disorders of the gut microbiota structure and increased the richness and diversity of intestinal microbial species in T1DM mice. At the genus level, the populations of several crucial bacteria, such as Akkermansia, Parabacteroides, and Muribaculum increased in the PWE treatment group but the abundance of Ruminiclostridium and Oscillibacter decreased. CONCLUSIONS Treatment with PWE can ameliorate hyperglycemic symptoms in STZ‐induced T1DM mice, and the anti‐diabetic effect of PWE was related to the amelioration of gut microbial structural disorder and the enrichment of functional bacteria. © 2022 Society of Chemical Industry.

show abstract

Section: Discussionsupporting

confidence: 47%

Section: Discussionmentioning

confidence: 99%

Anti‐diabetic and gut microbiota modulation effects of sacha inchi (Plukenetia volubilis L.) leaf extract in streptozotocin‐induced type 1 diabetic mice

et al. 2022

View full text Add to dashboard Cite

show abstract

“…Roseburia is a butyrate-producing genus, and butyrate could significantly inhibit the relative abundances of LPS-producing phyla, increase sestrin 2 and coactivator 2 expression in the liver of mice, and impair type 2 diabetes. 21,22 Bacteroides is a bacterial genus negatively associated with obesity 23 and produces short-chain fatty acids. 24 The abundance of Actinobacteria increased in obese mice in a previous study; 25 in the present study, this rise occurred in the BL21 group.…”

Section: ■ Discussionmentioning

confidence: 99%

Bifidobacterium longum subsp. longum Remodeled Roseburia and Phosphatidylserine Levels and Ameliorated Intestinal Disorders and liver Metabolic Abnormalities Induced by High-Fat Diet

Sun

et al. 2020

J. Agric. Food Chem.

View full text Add to dashboard Cite

Bifidobacterium longum is considered as a potential supplement in antiobesity treatment; however, the underlying molecular mechanism has rarely been studied. To understand the contributions of B. longum subsp. longum (BL21) in the prevention of obesity, we investigated alterations in the liver metabonomic phenotype and gut microbiota by ultraperformance liquid chromatography coupled with quadrupole time-of-flight mass spectrometry and 16S ribosomal RNA gene sequencing in C57BL/6J male mice orally administered with BL21 for 8 weeks [high-fat diet (HFD)]. BL21 at 1 × 109 CFU·day-1 per mouse reduced the weight of mice by 16.9% relative to that of the mice fed with HFD and significantly lowered the serum levels of total cholesterol, triglycerides, and low-density lipoprotein cholesterol. BL21 also ameliorated fat vacuolization in liver cells and epididymal fat accumulation. BL21 also lowered the Firmicutes/Bacteroidetes ratio, regulated liver remodeling in glycerophospholipids, and alleviated the levels of d-tryptophan. A positive correlation between the butyrate-producing strain Roseburia and the cell membrane component phosphatidylserine was found for the first time. Thus, BL21 can potentially prevent mice from being obese by rebalancing the gut microbiota and glycerophospholipid metabolism. BL21 can be a promising dietary supplement for weight control.

show abstract

“… 23 , 24 The role of EN formulas in diabetic patients is to provide the required macro- and micronutrients, including part or all of the carbohydrates, proteins, fats, vitamins and minerals needed, which could reduce the risk of malnutrition or overnutrition in diabetic patients. 25 , 26 It is generally believed that EN formulas are beneficial to health because they improve glycemic control, prevent intestinal barrier dysfunction, and maintain the integrity of mucosal functioning. 27 Whey protein can reduce blood glucose and improve oxidative stress, anti-inflammatory and immune regulation.…”

Section: Introductionmentioning

confidence: 99%

Nutritional Effects of the Enteral Nutritional Formula on Regulation of Gut Microbiota and Metabolic Level in Type 2 Diabetes Mellitus Mice

Wei¹,

Jia²,

Xue³

et al. 2021

DMSO

View full text Add to dashboard Cite

Purpose Due to the adverse effects of antidiabetic drugs, nowadays, nutraceuticals have been of much interest to investigators. Therefore, the present study aimed to explore the potential effects of enteral nutritional (EN) formulas on the gut microbiota and metabolic regulation of type 2 diabetes mellitus (T2DM) mice and compare the differences between whey protein and soy protein. Methods EN formulas made of whey protein or soy protein were administered for five weeks and then mice tissue samples were obtained to examine the metabolic parameters and histopathology of the pancreas, liver, jejunum and colon. 16S rRNA V3-V4 region gene sequencing was used to analyze the changes in the gut microbiota. Results After the five-week intervention, the alpha diversity had recovered slightly, and the soy protein group (SPG) achieved a better effect than the whey protein group (LPG). The overall composition of gut microbiota was regulated. The abundance of Bacteroidetes and TM7 had raised significantly and the abundance of Firmicutes and Deferribacteres had declined after treatment, with no significant difference between the LPG and SPG. The types of beneficial bacteria were increased at the genus and species level. The level of hexokinase (HK) and pyruvate kinase (PK) had significantly recovered and inhibited the level of α-glucosidase. In addition, the EN formulas treatment reduced the levels of inflammatory factor (TNF-α) in liver and muscle. The level of glucose transporter type 2 (GLUT-2) levels in the liver and intestine also significantly increased. Moreover, the metabolism regulation of the SPG was better than that of the LPG. The EN formulas treatment improved the pancreas, liver, jejunum and colon histology. Conclusion The EN formulas regulated the overall structure of the gut microbiota and improved the metabolic level in streptozotocin/high-fat diet (STZ/HFD) diabetic mice. Therefore, EN formula may potentially become an effective nutritional adjunctive therapy for T2DM.

show abstract

Effect of a Chinese medical nutrition therapy diet on gut microbiota and short chain fatty acids in the simulator of the human intestinal microbial ecosystem (SHIME)

Cited by 18 publications

References 43 publications

Anti‐diabetic and gut microbiota modulation effects of sacha inchi (Plukenetia volubilis L.) leaf extract in streptozotocin‐induced type 1 diabetic mice

Anti‐diabetic and gut microbiota modulation effects of sacha inchi (Plukenetia volubilis L.) leaf extract in streptozotocin‐induced type 1 diabetic mice

Bifidobacterium longum subsp. longum Remodeled Roseburia and Phosphatidylserine Levels and Ameliorated Intestinal Disorders and liver Metabolic Abnormalities Induced by High-Fat Diet

Nutritional Effects of the Enteral Nutritional Formula on Regulation of Gut Microbiota and Metabolic Level in Type 2 Diabetes Mellitus Mice

Contact Info

Product

Resources

About